Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a  pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs today announced that it has entered into a collaboration agreement with Montreal-Based company for the purposes of advancing the development of Sunshine  Biopharma’s anticancer compound, Adva-27a. The goal of this collaboration is to develop and  implement chemical synthesis procedures for Adva-27a and test the resulting material in various  types of cancer cells grown in culture. Based on the cell culture results, Sunshine’s drug  development partner will conduct mice studies in preparation for entry of Adva-27a into clinical  trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and  will be performed at McGill University’s Jewish General Hospital in Montreal, Canada. 

“We are delighted to be working with our new Montreal-Based partner and their fully integrated  team of experts in chemical synthesis, cell culture assays and mice studies,” said Camille  Sebaaly, CFO of Sunshine Biopharma. 

About Sunshine Biopharma and Adva-27a 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain  events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not 

be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information: 

Sunshine Biopharma, Inc. 

Camille Sebaaly, CFO 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com